Rickets and Osteomalacia

1. Clinical Overview

Summary

Rickets and Osteomalacia represent two age-dependent manifestations of the same fundamental pathological process: defective mineralisation of bone matrix (osteoid) due to inadequate calcium, phosphate, or both. The critical distinction lies in skeletal maturity. Rickets affects growing children with open growth plates (physes), resulting in characteristic skeletal deformities including bowing of long bones, growth retardation, and metaphyseal abnormalities. Osteomalacia occurs in adults with fused growth plates, presenting as diffuse bone pain, proximal myopathy, and pathognomonic radiological findings including pseudofractures (Looser's zones). [1,2]

The underlying aetiology is multifactorial but globally dominated by Vitamin D Deficiency (nutritional rickets/osteomalacia), which remains a significant public health problem despite being entirely preventable. Vitamin D deficiency prevalence has resurged in developed nations due to reduced sunlight exposure from indoor lifestyles, widespread sunscreen use, and dietary changes. High-risk populations include exclusively breastfed infants without supplementation, individuals with darker skin pigmentation living at northern latitudes, elderly institutionalised patients, and those with malabsorptive gastrointestinal disorders. [3,4]

Beyond nutritional causes, genetic forms of rickets—most notably X-Linked Hypophosphataemic Rickets (XLH)—represent important differential diagnoses resistant to standard vitamin D supplementation. Renal causes including chronic kidney disease (CKD-MBD) and hereditary renal tubular disorders (Fanconi syndrome) disrupt phosphate homeostasis or vitamin D activation. Rare causes include tumour-induced osteomalacia (oncogenic hypophosphataemia) mediated by fibroblast growth factor 23 (FGF-23) hypersecretion. [5,6]

Treatment fundamentals involve high-dose vitamin D and calcium supplementation for nutritional forms, with disease-specific approaches for genetic and acquired phosphopenic variants. Surgical intervention addresses severe skeletal deformities using guided growth techniques (temporary hemiepiphysiodesis) or corrective osteotomy. Emerging therapies including burosumab (anti-FGF23 monoclonal antibody) have revolutionised management of XLH and tumour-induced osteomalacia. [7,8]

Key Facts

Definitions:

• Rickets: Defective mineralisation affecting both the growth plate (endochondral ossification) and metaphyseal bone, occurring exclusively in children before physeal closure.
• Osteomalacia: Defective mineralisation of osteoid (unmineralised bone matrix) in adults after skeletal maturity.

Pathological Hallmark:

• Accumulation of unmineralised or hypomineralised osteoid matrix leading to structurally weak, deformable bone.

Principal Aetiology:

• Vitamin D deficiency (> 90% of cases globally) secondary to inadequate sunlight exposure, dietary insufficiency, or malabsorption. [3]

Clinical Phenotype (Rickets - Children):

• Skeletal: Bowing deformities (genu varum/valgum), metaphyseal widening (wrist/ankle flaring), rachitic rosary (costochondral junction prominence), craniotabes (soft skull), delayed fontanelle closure
• Growth: Short stature, failure to thrive
• Neuromuscular: Hypotonia, delayed motor milestones, hypocalcaemic seizures (severe cases)

Clinical Phenotype (Osteomalacia - Adults):

• Pain: Diffuse bone/joint pain (pelvis, spine, ribs), tenderness to percussion
• Muscle: Proximal myopathy (difficulty rising from chair, waddling gait)
• Fractures: Insufficiency fractures, vertebral compression fractures

Diagnostic Biochemistry:

• Calcium: Low or low-normal (maintained by secondary hyperparathyroidism)
• Phosphate: Low (renal phosphate wasting from PTH excess)
• Alkaline Phosphatase (ALP): Markedly elevated (osteoblast hyperactivity)
• PTH: Elevated (compensatory secondary hyperparathyroidism)
• 25-Hydroxyvitamin D [25(OH)D]: Deficient (less than 25 nmol/L or less than 10 ng/mL)

Clinical Pearls

"The Waddling Gait of Osteomalacia": The characteristic waddling, antalgic gait in osteomalacia patients arises from proximal muscle weakness (myopathy), not primary bone pain. Vitamin D deficiency directly impairs skeletal muscle function through impaired calcium flux and mitochondrial dysfunction. This myopathy affects hip abductors (gluteus medius) and knee extensors (quadriceps), producing the Trendelenburg gait pattern frequently misdiagnosed as neurological or orthopaedic hip pathology. [9]

"Looser's Zones: The Pathognomonic Sign": Looser's zones (pseudofractures, Milkman fractures) represent the radiological hallmark of osteomalacia. These lucent bands appear as ribbon-like radiolucencies oriented perpendicular to the cortical surface, typically bilateral and symmetrical. Predilection sites include femoral neck (medial cortex), pubic rami, ribs, scapular borders, and proximal ulna. They represent incomplete stress fractures attempting repair with unmineralised osteoid. Their presence is virtually diagnostic of osteomalacia. [10]

"Not Just Dietary Insufficiency": If a child demonstrates persistent rickets despite adequate vitamin D supplementation (compliance verified), suspect non-nutritional aetiologies. Hypophosphataemic rickets (renal phosphate wasting) and Vitamin D-Dependent Rickets (genetic defects in vitamin D metabolism or receptor function) require active vitamin D metabolites (calcitriol) and phosphate supplementation, not cholecalciferol. Genetic testing and specialist referral become mandatory. [11]

"The Dark Skin Paradox": Melanin functions as a natural ultraviolet filter, reducing cutaneous vitamin D synthesis efficiency by 95-99% in Fitzpatrick skin types V-VI. Consequently, individuals with darker skin pigmentation residing at northern latitudes (> 37° latitude: UK, Canada, Northern Europe) demonstrate dramatically higher vitamin D deficiency prevalence. This population requires 3-5 times higher sun exposure duration or routine supplementation. Recognition of this disparity prevents delayed diagnosis. [12]

"Rickets vs Child Abuse": Multiple fractures in an infant with rickets can mimic non-accidental injury (NAI). Key discriminating features include metaphyseal abnormalities (cupping/fraying) and elevated ALP in rickets versus metaphyseal corner fractures and posterior rib fractures in NAI. However, these conditions can coexist. Always consider skeletal survey, biochemical screening (Ca, PO4, ALP, vitamin D, PTH), and multidisciplinary safeguarding assessment. [13]

---

2. Epidemiology

Global Burden and Demographics

Despite being a preventable disease, rickets and osteomalacia persist as significant global health problems with resurging incidence in developed nations.

Rickets Prevalence:

• Global: Estimated 1-15% of children in high-risk populations (South Asia, Middle East, Sub-Saharan Africa). [3]
• Developed Nations: 2-5 per 100,000 children (resurging incidence in UK, Canada, USA, Australia since 1990s). [14]
• Peak Age: 6-24 months for nutritional rickets (coincides with rapid growth phase and weaning from fortified formula).

Osteomalacia Prevalence:

• Elderly Institutionalised: 15-25% prevalence in nursing home residents (limited sun exposure, reduced vitamin D synthesis capacity). [15]
• Immigrant Populations: Increased prevalence in Asian immigrants to Western countries (cultural clothing practices, dietary patterns).
• Post-Bariatric Surgery: 50-70% develop vitamin D deficiency within 2 years (malabsorption). [16]

High-Risk Populations

Infants and Children:

• Exclusively breastfed without vitamin D supplementation (breast milk contains only 25-78 IU/L)
• Premature infants (increased phosphate demands)
• Dark-skinned infants in northern climates
• Dietary restrictions (vegan diets, cow's milk protein allergy)
• Chronic illness (malabsorption syndromes, chronic kidney disease)

Adults:

• Elderly (reduced cutaneous synthesis, reduced dietary intake, reduced mobility)
• Institutionalised/housebound individuals
• Cultural/religious clothing practices limiting sun exposure (hijab, burqa)
• Chronic kidney disease stages 3-5 (impaired 1α-hydroxylation)
• Malabsorptive disorders (coeliac disease, Crohn's disease, post-gastrectomy)
• Chronic liver disease (impaired 25-hydroxylation)
• Anticonvulsant therapy (phenytoin, carbamazepine accelerate vitamin D catabolism)

Aetiological Classification

1. Calcipenic Rickets/Osteomalacia (Calcium or Vitamin D Deficiency)

Nutritional:

• Vitamin D deficiency (inadequate sunlight, dietary insufficiency)
• Calcium deficiency (low dietary intake, particularly in vegan diets)

Malabsorptive:

• Coeliac disease
• Inflammatory bowel disease (Crohn's disease)
• Post-bariatric surgery (gastric bypass, sleeve gastrectomy)
• Pancreatic insufficiency (cystic fibrosis, chronic pancreatitis)
• Biliary disease (cholestatic liver disease impairs fat-soluble vitamin absorption)

Metabolic Defects:

• Vitamin D-Dependent Rickets Type 1 (VDDR1): 1α-hydroxylase deficiency (CYP27B1 mutations)
• Vitamin D-Dependent Rickets Type 2 (VDDR2): Vitamin D receptor mutations (hereditary vitamin D-resistant rickets)
• Chronic liver disease (impaired 25-hydroxylation)
• Chronic kidney disease (impaired 1α-hydroxylation)

2. Phosphopenic Rickets/Osteomalacia (Phosphate Deficiency)

Hereditary:

• X-Linked Hypophosphataemic Rickets (XLH): PHEX gene mutations (most common hereditary form; prevalence 1:20,000)
• Autosomal Dominant Hypophosphataemic Rickets (ADHR): FGF23 mutations
• Autosomal Recessive Hypophosphataemic Rickets (ARHR): DMP1 or ENPP1 mutations
• Hereditary Hypophosphataemic Rickets with Hypercalciuria (HHRH): SLC34A3 mutations

Acquired:

• Tumour-Induced Osteomalacia (TIO): FGF23-secreting mesenchymal tumours (phosphaturic mesenchymal tumour)
• Fanconi Syndrome: Proximal renal tubular dysfunction (phosphate, glucose, amino acid wasting)
  • "Causes: Cystinosis, Wilson's disease, heavy metal toxicity, multiple myeloma"
• Prolonged antacid use (aluminium-containing antacids bind dietary phosphate)
• Iron polymaltose therapy (iatrogenic FGF23 excess)

3. Mineralisation Inhibitors

• Hypophosphatasia: Tissue-nonspecific alkaline phosphatase (TNSALP) deficiency
• Chronic bisphosphonate therapy (rare)
• Aluminium toxicity (chronic renal failure patients on dialysis)
• Fluoride toxicity

---

3. Pathophysiology

Vitamin D Metabolism: The Sequential Activation Pathway

Vitamin D functions as a steroid hormone essential for calcium-phosphate homeostasis and bone mineralisation. Understanding the multi-step activation pathway is critical for recognising where defects occur.

Step 1: Cutaneous Synthesis

• Location: Skin (stratum basale and stratum spinosum)
• Reaction: UVB radiation (290-315 nm wavelength) photolyses 7-dehydrocholesterol to previtamin D3
• Thermal Isomerisation: Previtamin D3 spontaneously converts to cholecalciferol (vitamin D3) over 48-72 hours
• Efficiency Factors: Latitude, season, time of day, skin pigmentation, age, sunscreen use
• Age Effect: Cutaneous synthesis capacity declines 75% between ages 20-70 years [17]

Step 2: Hepatic 25-Hydroxylation

• Location: Liver (hepatocytes)
• Enzyme: 25-Hydroxylase (CYP2R1, CYP27A1)
• Product: 25-Hydroxyvitamin D [25(OH)D] = Calcidiol
• Significance: This is the major circulating form and storage reservoir measured clinically
• Half-Life: 2-3 weeks (reflects long-term vitamin D status)
• Impairment: Severe chronic liver disease (cirrhosis, hepatic failure)

Step 3: Renal 1α-Hydroxylation

• Location: Kidney (proximal convoluted tubule)
• Enzyme: 1α-Hydroxylase (CYP27B1)
• Product: 1,25-Dihydroxyvitamin D [1,25(OH)₂D] = Calcitriol (biologically active hormone)
• Regulation:
  • "Upregulated by: PTH (primary regulator), hypophosphataemia, hypocalcaemia"
  • "Downregulated by: FGF23, hyperphosphataemia, hypercalcaemia (negative feedback)"
• Half-Life: 4-6 hours (tight physiological control)
• Impairment: Chronic kidney disease (CKD) stages 3-5, VDDR Type 1 (genetic 1α-hydroxylase deficiency)

The Vicious Cycle of Vitamin D Deficiency

Stage 1: Calcium Malabsorption

• Vitamin D deficiency → Reduced calcitriol → Decreased intestinal calcium absorption (duodenum/jejunum)
• Normally 30-40% dietary calcium absorbed; drops to less than 15% in deficiency
• Result: Hypocalcaemia (ionised calcium falls)

Stage 2: Compensatory Hyperparathyroidism

• Calcium-sensing receptors (CaSR) on parathyroid chief cells detect hypocalcaemia
• Triggers PTH secretion (secondary hyperparathyroidism)
• PTH actions:
  1. Bone resorption: Activates osteoclasts → calcium mobilisation from skeleton
  2. Renal calcium retention: Increased distal tubule calcium reabsorption
  3. Renal phosphate wasting: Inhibits proximal tubule phosphate reabsorption → hypophosphataemia
  4. Renal 1α-hydroxylase activation: Increases calcitriol production (partially compensatory)

Stage 3: Disturbed Calcium-Phosphate Product

• Normal bone mineralisation requires adequate calcium × phosphate product
• Threshold for hydroxyapatite crystal deposition: Ca × PO₄ > 30-40 mg²/dL²
• In rickets/osteomalacia: Low phosphate (PTH-driven wasting) prevents mineralisation despite normal/normalised calcium

Stage 4: Defective Mineralisation

• Osteoblasts continue producing osteoid matrix (type I collagen scaffold)
• However, inadequate calcium-phosphate product prevents hydroxyapatite crystal deposition
• Result: Accumulation of thick seams of unmineralised osteoid
• Histology (gold standard): Osteoid seam width > 12-15 μm (normal less than 12 μm)

Stage 5: Skeletal Consequences

In Children (Rickets):

• Growth Plate Disruption:
  • Normal endochondral ossification requires mineralisation of cartilage matrix
  • Defective mineralisation → disorganised, widened, irregular growth plates
  • Radiological "cupping and fraying" of metaphyses
• Weight-Bearing Deformities: Soft, deformable bone bends under mechanical stress
  • Genu varum (bow legs) in toddlers
  • Genu valgum (knock knees) in older children
• Costochondral Junction Enlargement: "Rachitic rosary" (palpable beading along anterior chest wall)

In Adults (Osteomalacia):

• Pseudofractures (Looser's Zones):
  • Insufficiency stress fractures healing with unmineralised osteoid
  • Appear as lucent bands perpendicular to cortex
• Generalised Bone Pain: Periosteal irritation, microfractures
• Proximal Myopathy: Vitamin D deficiency directly impairs muscle function (independent of bone effects)

Phosphopenic Rickets/Osteomalacia: FGF23-Mediated Pathway

In hypophosphataemic rickets (XLH, TIO), the primary defect is renal phosphate wasting driven by excess Fibroblast Growth Factor 23 (FGF23).

FGF23 Physiology:

• Secreted by osteocytes in response to high phosphate, calcitriol, or PTH
• Acts on kidneys via FGFR1/Klotho receptor complexes
• Effects:
  1. Inhibits proximal tubule phosphate reabsorption (downregulates Na-Pi cotransporters)
  2. Suppresses 1α-hydroxylase (reduces calcitriol production)
  3. Upregulates 24-hydroxylase (accelerates calcitriol degradation)

Pathological FGF23 Excess:

• XLH: PHEX gene mutations prevent FGF23 degradation → persistent FGF23 excess
• TIO: Mesenchymal tumours secrete FGF23 → paraneoplastic syndrome
• Result: Severe hypophosphataemia + inappropriately normal/low calcitriol + normal calcium
• Rickets/osteomalacia develops despite normal vitamin D stores

---

4. Clinical Presentation

Rickets (Paediatric Presentation)

Constitutional Symptoms

• Failure to Thrive: Poor weight gain, crossing centile lines downward
• Irritability and Lethargy: Bone/muscle pain contributes to fussiness
• Delayed Developmental Milestones: Motor delay (sitting, standing, walking)
• Hypotonia: Generalised muscle weakness ("floppy infant")

Skeletal Manifestations

Cranial:

• Craniotabes: Soft, "ping-pong ball" skull (posterior parietal/occipital bones deform under pressure)
• Frontal Bossing: Prominent forehead due to thickened frontal bones
• Delayed Fontanelle Closure: Anterior fontanelle remains open beyond 18-24 months
• Flattening of Occiput: From prolonged supine positioning (soft skull deforms)

Thoracic:

• Rachitic Rosary: Prominence of costochondral junctions creating palpable "beads" along anterior chest
• Harrison's Sulcus: Horizontal indentation along lower rib cage at diaphragm insertion (from soft ribs pulled inward during breathing)
• Pectus Carinatum: Pigeon chest deformity (forward protrusion of sternum)
• Respiratory Complications: Increased risk of pneumonia, respiratory failure (rib cage instability, muscle weakness)

Upper Limbs:

• Metaphyseal Widening: "Double malleoli" appearance at wrists (distal radius/ulna flaring)
• Delayed Epiphyseal Ossification: Visible on radiographs

Lower Limbs:

• Genu Varum (Bow Legs): Most common in toddlers (age 1-3 years) bearing weight on soft bones
• Genu Valgum (Knock Knees): Can develop in older children (age 3-6 years)
• Ankle/Knee Swelling: Metaphyseal enlargement
• Short Stature: Growth retardation from growth plate dysfunction
• Antalgic Gait: Bone pain causing limping

Spinal:

• Kyphoscoliosis: Spinal curvature deformities
• Delayed Walking: Often presenting complaint bringing child to medical attention

Neuromuscular Manifestations

• Hypocalcaemic Tetany: Carpopedal spasm, Trousseau's sign, Chvostek's sign
• Hypocalcaemic Seizures: Medical emergency (generalised tonic-clonic seizures)
• Laryngospasm: Stridor, respiratory distress (life-threatening)
• Proximal Myopathy: Difficulty standing, climbing stairs

Dental Manifestations

• Delayed Tooth Eruption: Primary and permanent dentition
• Enamel Hypoplasia: Weak, defective enamel (increased caries risk)
• Dental Abscesses: Particularly severe in XLH (dentin defects allow bacterial invasion)

Osteomalacia (Adult Presentation)

Musculoskeletal Symptoms

Bone Pain:

• Character: Diffuse, deep, aching bone/joint pain
• Distribution: Pelvis, lower spine, ribs, hips, lower limbs
• Aggravating Factors: Weight-bearing, pressure, percussion tenderness
• Severity: Often severe enough to cause immobility

Proximal Muscle Weakness (Myopathy):

• Pattern: Symmetrical proximal muscle weakness
• Functional Deficits:
  • Difficulty rising from chair/toilet without arm support
  • Difficulty climbing stairs (pulling on banister required)
  • Difficulty raising arms above head (combing hair, reaching shelves)
• Gait Abnormality: Waddling gait (Trendelenburg pattern from gluteus medius weakness)
• Mechanism: Vitamin D deficiency directly impairs muscle function (vitamin D receptor expression in skeletal muscle)

Fractures:

• Insufficiency Fractures: Fractures occurring with minimal/no trauma
• Sites: Femoral neck, pubic rami, sacrum, ribs, vertebrae
• Presentation: Often occult, progressive pain

Constitutional Symptoms

• Fatigue: Profound, debilitating tiredness
• Mood Changes: Depression, cognitive impairment (vitamin D deficiency associated)
• Sleep Disturbance: Chronic pain disrupting sleep

Complications in Specific Populations

Women with Prior Severe Childhood Rickets:

• Pelvic Deformity: Triradiate/funnel pelvis from childhood bowing
• Obstructed Labour: Cephalopelvic disproportion requiring caesarean section
• Prevalence: Historical problem; rare in modern practice with early treatment

Elderly:

• Falls Risk: Myopathy + pain + fractures create falls-fracture cycle
• Vertebral Compression Fractures: Progressive kyphosis ("dowager's hump")
• Functional Decline: Immobility, loss of independence

---

5. Investigations

Biochemical Profile: The Rickets/Osteomalacia Screen

A systematic biochemical panel distinguishes calcipenic from phosphopenic forms and guides targeted treatment.

First-Line Blood Tests

Serum Calcium (Total and Ionised):

• Calcipenic Rickets: Low or low-normal (PTH compensation maintains levels)
• Phosphopenic Rickets: Normal
• Severe Acute Cases: Frank hypocalcaemia (less than 2.0 mmol/L) → seizure risk

Serum Phosphate:

• Calcipenic Rickets: Low (PTH-driven renal wasting)
• Phosphopenic Rickets: Markedly low (less than 0.6 mmol/L in adults, less than 1.0 mmol/L in children)
• Key Discriminator: Isolated hypophosphataemia suggests phosphopenic aetiology

Alkaline Phosphatase (ALP):

• Both Forms: Markedly elevated (often 2-10× upper limit of normal)
• Mechanism: Osteoblast hyperactivity (futile attempt at bone formation)
• Monitoring: ALP normalisation (usually 3-6 months) indicates treatment response
• Pitfall: Physiologically elevated in children (growth); compare age-matched reference ranges

Parathyroid Hormone (PTH):

• Calcipenic Rickets: Elevated (secondary hyperparathyroidism)
• Phosphopenic Rickets: Normal or mildly elevated
• Interpretation: Elevated PTH + low vitamin D confirms calcipenic aetiology

25-Hydroxyvitamin D [25(OH)D]:

• Deficiency: less than 25 nmol/L (less than 10 ng/mL)
• Insufficiency: 25-50 nmol/L (10-20 ng/mL)
• Sufficiency: > 50 nmol/L (> 20 ng/mL); optimal > 75 nmol/L (> 30 ng/mL)
• Calcipenic Rickets: Deficient
• Phosphopenic Rickets: Normal or high (compensatory hyperproduction)

1,25-Dihydroxyvitamin D [Calcitriol]: (Specialist Test)

• VDDR Type 1: Low (1α-hydroxylase deficiency)
• VDDR Type 2: High (receptor resistance)
• Phosphopenic Rickets: Low-normal (FGF23 suppression)
• Not Routine: Reserved for complex cases

Second-Line Investigations

Renal Function:

• Urea, Creatinine, eGFR: Assess for chronic kidney disease (CKD-MBD)
• Urine Phosphate/Creatinine Ratio: Identifies renal phosphate wasting
• Tubular Reabsorption of Phosphate (TRP):
  • "Formula: TRP = 1 - (Urine PO₄ × Serum Creatinine) / (Serum PO₄ × Urine Creatinine)"
  • "Normal: > 85%"
  • "Renal Phosphate Wasting: less than 85% (confirms tubular defect)"

Urine Calcium:

• Calcipenic Rickets: Low urinary calcium excretion (increased renal reabsorption)
• HHRH: High urinary calcium (discriminates from XLH which has low urinary calcium)

Fasting Urine Calcium/Creatinine Ratio:

• Helps distinguish hypophosphataemic subtypes

FGF23 Level: (Specialist Centre)

• XLH, TIO: Elevated or inappropriately normal (should be suppressed with hypophosphataemia)
• Emerging Diagnostic Tool: Increasingly available

Genetic Testing

Indications:

• Rickets resistant to standard vitamin D therapy
• Family history of rickets/short stature/bowing
• Hypophosphataemia with normal vitamin D
• Early-onset osteomalacia

Genes Tested:

• XLH: PHEX gene sequencing
• VDDR1: CYP27B1 mutations
• VDDR2: VDR (vitamin D receptor) mutations
• ADHR: FGF23 mutations
• ARHR: DMP1, ENPP1 mutations
• Hypophosphatasia: ALPL mutations

Next-Generation Sequencing Panels: Analyse multiple rickets-associated genes simultaneously

Radiological Investigations

Rickets: Characteristic Growth Plate Changes

Standard Films:

• Anteroposterior Wrists: Most sensitive site for early rickets detection
• Anteroposterior Knees: Assess lower limb changes
• Lateral Chest: Rachitic rosary visible
• Anteroposterior Pelvis: Coxa vara, triradiate pelvis (severe cases)
• Full Leg Alignment Films (Standing): Mechanical axis deviation, bowing severity

Radiological Features:

Metaphysis:

• Cupping: Concave, "champagne glass" deformity at metaphyseal-diaphyseal junction
• Fraying: Irregular, brush-like appearance at metaphyseal margin
• Widening: Increased distance between metaphysis and epiphysis
• Loss of Sharp Zone of Provisional Calcification: The normally sharp white line at growth plate becomes indistinct

Growth Plate:

• Widened Physis: Thickened radiolucent band (> 2 mm abnormal)
• Irregular Surface: Loss of smooth contour

Diaphysis:

• Bowing Deformities:
  • Genu varum (tibia/femur bowing laterally)
  • Genu valgum (tibia/femur bowing medially)
• Coarse Trabeculation: Abnormal trabecular pattern
• Subperiosteal Resorption: From secondary hyperparathyroidism

Healing Changes:

• Dense Metaphyseal Band: Appears with treatment (transverse sclerosis = "growth recovery lines")
• Gradual Restoration: Normal architecture returns over 3-12 months

Osteomalacia: Pseudofractures and Generalised Osteopenia

Standard Films:

• Anteroposterior Pelvis: Looser's zones in pubic rami, femoral necks
• Lateral Spine: Vertebral deformities
• Chest: Rib pseudofractures
• Proximal Femurs: Femoral neck lucencies

Radiological Features:

Looser's Zones (Pseudofractures, Milkman Fractures):

• Appearance: Radiolucent ribbons/bands perpendicular to cortex, often with sclerotic margins
• Characteristics:
  • Bilateral and symmetrical (unlike traumatic fractures)
  • Incomplete (do not traverse entire width of bone)
  • No associated soft tissue swelling/callus
• Predilection Sites (Looser's transformation zones):
  • Femoral neck (medial cortex)
  • Pubic rami (superior and inferior)
  • Ribs (lateral aspects)
  • Scapula (axillary border)
  • Proximal ulna
  • Metatarsals
• Pathognomonic: Virtually diagnostic of osteomalacia

Generalised Changes:

• Osteopenia: Diffuse bone demineralisation (radiolucent appearance)
• Coarse Trabecular Pattern: "Ground glass" appearance
• Cortical Thinning: Reduced cortical thickness
• Vertebral Deformities:
  • "Codfish Vertebrae: Biconcave endplate depressions (from disc herniation into weakened bone)"
  • "Compression Fractures: Wedging, height loss"
• Protrusio Acetabuli: Medial migration of femoral head into pelvis

Advanced Imaging

Bone Scintigraphy (Tc-99m MDP Bone Scan):

• Indication: Localise occult pseudofractures/stress fractures
• Appearance: Multiple "hot spots" at sites of increased bone turnover

Whole-Body MRI:

• Indication: Tumour-induced osteomalacia (localise FGF23-secreting tumour)
• Sensitivity: Superior to conventional imaging for small mesenchymal tumours

FDG-PET/CT:

• Indication: Tumour-induced osteomalacia (metabolically active tumour detection)

Dual-Energy X-Ray Absorptiometry (DEXA):

• Finding: Low bone mineral density (BMD)
• Limitation: Cannot distinguish osteomalacia from osteoporosis; biochemical correlation essential

Bone Biopsy (Gold Standard - Rarely Performed)

Indications:

• Diagnostic uncertainty despite full biochemical/radiological workup
• Research purposes

Technique:

• Trans-iliac crest biopsy with tetracycline double-labelling
• Tetracycline administered 2-week intervals before biopsy (fluorescence labels sites of active mineralisation)

Histological Hallmarks:

• Increased Osteoid Volume: Thick seams of unmineralised osteoid (> 12-15 μm; normal less than 12 μm)
• Increased Osteoid Surface: > 20% of trabecular surface (normal less than 10-15%)
• Prolonged Mineralisation Lag Time: Time for osteoid to mineralise increased
• Reduced Mineralisation Apposition Rate: Tetracycline labels separated by reduced distance

---

6. Management

Nutritional Rickets/Osteomalacia: Vitamin D and Calcium Repletion

The cornerstone of management for calcipenic disease is high-dose vitamin D replacement combined with ensuring adequate calcium intake.

Vitamin D Replacement Strategies

Stoss Therapy (High-Dose Bolus):

• Regimen: Single large dose of vitamin D followed by maintenance
• Example:
  • "Children: 150,000-300,000 IU oral cholecalciferol (single dose or divided over 1-2 weeks)"
  • "Adults: 300,000-600,000 IU"
• Advantages: Ensures compliance, rapid repletion
• Disadvantages: Theoretical hypercalcaemia risk (monitor calcium)
• Follow-Up: Maintenance therapy essential (see below)

Daily High-Dose Therapy:

• Children:
  • "Age less than 1 year: 2000 IU daily for 12 weeks"
  • "Age 1-12 years: 3000-6000 IU daily for 12 weeks"
  • "Age > 12 years: 6000 IU daily for 8-12 weeks"
• Adults:
  • 3000-6000 IU daily for 8-12 weeks (loading phase)
• Advantages: Gradual, safe repletion
• Disadvantages: Requires compliance

Maintenance Therapy (After Repletion):

• Infants: 400 IU daily
• Children: 600-1000 IU daily
• Adults: 800-2000 IU daily
• High-Risk Populations: 2000-4000 IU daily lifelong

Monitoring:

• Serum calcium (weekly for first month if using Stoss therapy - risk of hypercalcaemia)
• 25(OH)D level at 3 months (target > 50 nmol/L, ideally > 75 nmol/L)
• ALP at 3 and 6 months (should normalise; persistent elevation suggests non-compliance or alternative diagnosis)
• PTH at 3 months (should normalise)

Calcium Supplementation

Daily Requirements:

• Infants 0-6 months: 200 mg
• Infants 7-12 months: 260 mg
• Children 1-3 years: 700 mg
• Children 4-8 years: 1000 mg
• Children 9-18 years: 1300 mg
• Adults 19-50 years: 1000 mg
• Adults > 50 years: 1200 mg

Supplementation:

• If dietary intake inadequate, supplement to meet daily requirements
• Forms: Calcium carbonate (40% elemental calcium), calcium citrate (21% elemental calcium; better absorbed in achlorhydria)
• Dosing: Typically 500-1000 mg elemental calcium daily in divided doses (absorption saturates at 500 mg)

Dietary Sources:

• Dairy products (milk, yoghurt, cheese)
• Fortified foods (orange juice, cereals)
• Green leafy vegetables (kale, broccoli)
• Almonds, tofu, sardines

Treatment Response

Clinical Improvement:

• Bone pain improves within weeks
• Muscle weakness improves within 2-3 months
• Growth velocity increases (children)

Biochemical Improvement:

• Calcium normalises within days-weeks
• Phosphate normalises within weeks
• PTH normalises within 1-3 months
• ALP normalisation: Key marker of healing (3-6 months)

Radiological Healing:

• Metaphyseal changes begin resolving within 2-4 weeks
• Dense metaphyseal bands appear (growth recovery lines)
• Complete radiological normalisation: 6-12 months
• Bowing deformities may gradually remodel (see surgical management)

Renal Osteodystrophy (CKD-MBD): Active Vitamin D Metabolites

Chronic kidney disease impairs 1α-hydroxylation, rendering standard cholecalciferol ineffective. Active vitamin D analogues bypass this defect.

Indications:

• CKD stages 3-5
• Vitamin D-Dependent Rickets Type 1 (1α-hydroxylase deficiency)

Agents:

Alfacalcidol (1α-Hydroxyvitamin D):

• Dose:
  • "Children: 0.01-0.1 mcg/kg/day"
  • "Adults: 0.25-1 mcg daily"
• Mechanism: Requires hepatic 25-hydroxylation (final step) to become active
• Advantage: Partially physiological (some hepatic regulation)

Calcitriol (1,25-Dihydroxyvitamin D):

• Dose:
  • "Children: 0.01-0.05 mcg/kg/day"
  • "Adults: 0.25-0.5 mcg daily"
• Mechanism: Fully active (no further metabolism required)
• Advantage: Direct action

Monitoring:

• Calcium and Phosphate: Weekly initially, then every 2-4 weeks (risk of hypercalcaemia/hyperphosphataemia)
• PTH: Target depends on CKD stage (CKD stage 5: PTH 2-9× upper limit of normal)
• Adjust Dose: Titrate to maintain calcium less than 2.55 mmol/L and phosphate in target range

Adjunctive Therapy:

• Phosphate Binders: Control hyperphosphataemia (calcium carbonate, sevelamer, lanthanum)
• Cinacalcet: Calcimimetic agent (reduces PTH in refractory secondary hyperparathyroidism)

Hypophosphataemic Rickets (XLH and Related Disorders)

Management requires both phosphate replacement and active vitamin D to promote phosphate absorption and suppress PTH.

Conventional Therapy:

Phosphate Supplements:

• Forms: Sodium/potassium phosphate solutions
• Dose:
  • "Children: 20-60 mg/kg/day elemental phosphorus (divided 4-5 doses)"
  • "Adults: 1-4 g/day elemental phosphorus (divided doses)"
• Timing: Frequent dosing essential (phosphate rapidly excreted)
• Side Effects: Gastrointestinal distress (diarrhoea, nausea)

Active Vitamin D (Calcitriol or Alfacalcidol):

• Dose:
  • "Children: 20-60 ng/kg/day calcitriol"
  • "Adults: 0.5-2 mcg/day calcitriol"
• Rationale: Enhances intestinal phosphate absorption, suppresses PTH (prevents secondary hyperparathyroidism from phosphate loading)

Monitoring:

• Calcium, phosphate every 3 months
• PTH every 6 months (risk of tertiary hyperparathyroidism)
• Renal ultrasound annually (risk of nephrocalcinosis from hypercalciuria)
• Alkaline phosphatase (treatment response marker)

Limitations of Conventional Therapy:

• Does not address underlying FGF23 excess
• Requires lifelong, frequent dosing (compliance challenges)
• Risk of nephrocalcinosis (25-70% of patients)
• Incomplete correction of biochemistry and growth

Revolutionary Targeted Therapy: Burosumab

Mechanism:

• Fully human monoclonal antibody against FGF23
• Blocks FGF23 action → restores renal phosphate reabsorption and 1α-hydroxylase activity

Indications:

• X-Linked Hypophosphataemic Rickets (XLH) in children and adults
• Tumour-Induced Osteomalacia (if tumour unresectable/unlocatable)
• FDA/EMA approved

Dosing:

• Children: 0.8-1.2 mg/kg subcutaneous every 2 weeks (weight-based tiering)
• Adults: 1 mg/kg (max 90 mg) subcutaneous every 4 weeks

Efficacy:

• Normalises serum phosphate in > 90% of patients [18]
• Improves rickets severity scores radiologically
• Improves growth velocity in children
• Improves pain, mobility, quality of life in adults
• Reduces need for conventional phosphate/calcitriol therapy

Monitoring:

• Serum phosphate (pre-dose and peak at 2 weeks initially)
• Calcium, PTH, vitamin D
• Renal imaging (reduced nephrocalcinosis risk vs conventional therapy)

Advantages Over Conventional Therapy:

• Addresses pathophysiological root cause
• Single injection every 2-4 weeks (improved compliance)
• Superior biochemical control
• Improved patient-reported outcomes

Cost Considerations:

• Expensive (~£40,000-60,000/year)
• Requires specialist centre management

Tumour-Induced Osteomalacia (TIO)

Curative Treatment: Tumour Resection

• Goal: Complete excision of FGF23-secreting tumour
• Result: Rapid normalisation of phosphate (within hours-days), biochemical cure
• Localisation Challenge: Tumours often small, occult (mesenchymal tumours in soft tissue/bone)
• Imaging: Whole-body MRI, FDG-PET/CT, selective venous sampling for FGF23 (if available)

Medical Management (Unresectable/Occult Tumour):

• Conventional phosphate/calcitriol therapy (as per XLH)
• Burosumab: Increasingly first-line for unresectable TIO (highly effective) [8]

Vitamin D-Dependent Rickets

VDDR Type 1 (1α-Hydroxylase Deficiency):

• Pathology: CYP27B1 mutations
• Treatment: Calcitriol or alfacalcidol (bypasses defective enzyme)
• Dose: 1-3 mcg/day calcitriol
• Prognosis: Excellent with lifelong replacement

VDDR Type 2 (Vitamin D Receptor Mutations):

• Pathology: VDR gene mutations (end-organ resistance)
• Presentation: Often severe, with alopecia (characteristic)
• Treatment:
  • Very high-dose calcitriol (5-60 mcg/day) + calcium (oral, IV)
  • Some patients resistant to all therapy (receptor completely non-functional)
• Prognosis: Variable; severe cases challenging

Surgical Management: Skeletal Deformity Correction

Indications

Residual Deformity After Medical Optimisation:

• Biochemical correction achieved (normalised ALP, PTH, phosphate, vitamin D)
• Persistent bowing causing functional impairment, pain, or cosmetic concern
• Age > 5-6 years (allow time for spontaneous remodelling)

Severe Progressive Deformity:

• Genu varum/valgum with mechanical axis deviation (MAD) > 10-15°
• Coxa vara with neck-shaft angle less than 110°

Contraindications to Surgery:

• Active rickets (ongoing metabolic disease) - must optimise medically first
• Inadequate nutrition/vitamin D stores (impaired healing)

Surgical Techniques

Guided Growth (Hemiepiphysiodesis):

• Principle: Modulate physeal growth by selectively restricting one side of growth plate (Hueter-Volkmann Law: compression inhibits growth, tension stimulates growth)
• Technique:
  • 8-Plates (tension band plates) placed across physis on convex side of deformity
  • Screws placed in epiphysis and metaphysis, plate bridges physis
  • Inhibits growth on that side, allows continued growth on opposite side → gradual correction
• Advantages:
  • Minimally invasive
  • Reversible (remove plates once corrected)
  • Gradual, physiological correction
• Disadvantages:
  • Requires open physes (not suitable for adults/adolescents near skeletal maturity)
  • Slow correction (1° per month)
  • Requires monitoring, potential repeat procedures
• Typical Rate: ~1° correction per month
• Removal: Once mechanical axis normalised (usually 12-24 months)

Corrective Osteotomy:

• Principle: Surgical bone cut to realign mechanical axis
• Indications:
  • Skeletally mature patients (closed physes)
  • Severe deformity unsuitable for guided growth
  • Failed guided growth
• Techniques:
  • "Opening/Closing Wedge Osteotomy: Single-level tibial/femoral osteotomy"
  • "Dome Osteotomy: Curved osteotomy (multiplanar correction)"
• Fixation: Internal (plates/screws) or external (Taylor Spatial Frame, Ilizarov)
• Advantages:
  • Immediate correction
  • Suitable for adults
• Disadvantages:
  • More invasive
  • "Risks: Nonunion, infection, neurovascular injury, compartment syndrome"
  • Requires bone healing (healing may be delayed in hypophosphataemic rickets)

Preoperative Optimisation:

• Ensure normalised biochemistry for ≥6 months before elective surgery
• In XLH: Consider perioperative burosumab (improved healing)

---

7. Prognosis and Complications

Disease Complications

Permanent Skeletal Sequelae (Untreated/Inadequately Treated Disease):

• Short Stature: Growth plate dysfunction causes permanent height reduction
• Limb Length Discrepancy: Asymmetrical bowing may cause leg length inequality
• Permanent Deformity: Bowing, genu varum/valgum, coxa vara
• Osteoarthritis: Abnormal joint mechanics accelerate degenerative changes (knee, hip, ankle)
• Spinal Deformities: Kyphosis, scoliosis
• Pelvic Deformity: Triradiate pelvis (historical; rare with modern treatment)

Acute Life-Threatening Complications:

• Hypocalcaemic Seizures: Generalised tonic-clonic seizures from severe hypocalcaemia
• Hypocalcaemic Tetany/Laryngospasm: Airway obstruction (stridor, respiratory failure)
• Cardiac Arrhythmias: Severe hypophosphataemia or hypocalcaemia
• Respiratory Failure: Chest wall instability (rib fractures, rachitic rosary), respiratory muscle weakness

Dental Complications:

• Enamel hypoplasia, delayed eruption
• Recurrent dental abscesses (particularly XLH - dentin defects)
• Orthodontic problems

Functional Impairment:

• Chronic pain (bone, muscle)
• Reduced mobility, disability
• Reduced quality of life

Treatment Complications

Vitamin D Toxicity (Hypervitaminosis D):

• Cause: Excessive dosing, inadequate monitoring
• Manifestations: Hypercalcaemia, hypercalciuria
• Symptoms: Nausea, vomiting, polyuria, polydipsia, confusion, lethargy
• Severe: Nephrocalcinosis, renal failure, cardiac arrhythmias
• Management: Stop vitamin D, hydration, furosemide (if severe), corticosteroids, bisphosphonates (severe cases)

Nephrocalcinosis:

• Risk Factors: High-dose calcitriol, phosphate supplementation (XLH), hypercalciuria
• Prevalence: 25-70% in conventionally-treated XLH patients [19]
• Monitoring: Annual renal ultrasound in high-risk patients
• Prevention: Monitor urinary calcium/creatinine ratio, optimise dosing

Tertiary Hyperparathyroidism:

• Mechanism: Prolonged phosphate supplementation → chronic PTH stimulation → autonomous PTH secretion
• Result: Hypercalcaemia, continued bone resorption despite treatment
• Management: Parathyroidectomy (if severe)

Surgical Complications:

• Infection, nonunion, malunion, neurovascular injury, compartment syndrome
• Recurrence of deformity (if metabolic disease inadequately controlled)
• Delayed healing (particularly hypophosphataemic rickets)

Prognosis

Nutritional Rickets/Osteomalacia:

• With Early Treatment: Excellent prognosis
  • Complete biochemical normalisation within 3-6 months
  • Radiological healing within 6-12 months
  • Growth catch-up (children)
  • Resolution of pain/myopathy (adults)
  • Bowing may spontaneously remodel in young children (less than 5 years); older children/adults may require surgery
• Delayed Treatment: Increased risk of permanent short stature, deformity

Hypophosphataemic Rickets (XLH):

• Conventional Therapy:
  • Improved but rarely normalised biochemistry
  • Reduced but persistent short stature, bowing
  • Lifelong therapy required
  • Risk of nephrocalcinosis, tertiary hyperparathyroidism
• Burosumab Era:
  • Marked improvement in biochemical control
  • Improved growth, reduced deformity
  • Improved quality of life
  • Long-term outcomes still being established

Renal Osteodystrophy:

• Prognosis tied to underlying CKD progression
• Ongoing CKD-MBD management required lifelong
• Renal transplantation improves bone disease (restores 1α-hydroxylase function)

---

8. Prevention

Public Health Strategies

Universal Infant Vitamin D Supplementation:

• UK Guidelines: All infants 0-12 months receive 400 IU/day (Department of Health)
• High-Risk Infants:
  • "Exclusively breastfed: 400 IU/day from birth"
  • "Formula-fed: Supplementation if less than 500 mL formula/day (formula fortified with ~400 IU/L)"
  • "Premature infants: 400-1000 IU/day"

Food Fortification:

• Milk, infant formula, margarine, cereals fortified with vitamin D
• Effective in countries with mandatory fortification (USA, Canada, Scandinavia)

Public Awareness Campaigns:

• Education on safe sun exposure (15-30 minutes midday sun several times/week for lighter skin; longer for darker skin)
• Balancing skin cancer prevention (sunscreen) with vitamin D synthesis

Targeted Supplementation for High-Risk Groups:

• Pregnant/Lactating Women: 400-600 IU/day (prevents neonatal rickets)
• Elderly: 800-2000 IU/day
• Dark-Skinned Individuals in Northern Latitudes: 1000-2000 IU/day
• Malabsorption Disorders: Higher doses (2000-6000 IU/day)
• Institutionalised/Housebound: Routine supplementation

Individual Prevention

Sun Exposure:

• Safe Sun Guidelines:
  • 15-30 minutes midday sun (10am-3pm) on face/arms several times/week
  • Without sunscreen (sunscreen SPF > 15 blocks 99% UVB)
  • Darker skin requires 3-5× longer exposure
  • "Balance: Enough for vitamin D but minimise skin cancer risk"

Dietary Sources:

• Fatty Fish: Salmon, mackerel, sardines (excellent sources; ~400-1000 IU per serving)
• Egg Yolks: ~40 IU per yolk
• Fortified Foods: Milk, cereals, orange juice
• Mushrooms: (UV-treated varieties have higher vitamin D)
• Limitation: Difficult to achieve adequate intake from diet alone (typical diet provides less than 200 IU/day)

Screening High-Risk Populations:

• Infants with failure to thrive, developmental delay, bony deformity
• Pregnant women (risk of neonatal rickets/hypocalcaemia)
• Elderly with unexplained falls, fractures, bone pain
• CKD patients (routine monitoring)

---

9. Special Populations

Rickets in Premature Infants ("Rickets of Prematurity")

Aetiology:

• Interruption of third-trimester placental calcium/phosphate transfer (80% of fetal mineral accretion occurs third trimester)
• Increased bone growth demands in rapidly growing preterm infant
• Phosphate deficiency (primary driver) + calcium deficiency

Risk Factors:

• Birth weight less than 1500 g
• Gestational age less than 32 weeks
• Prolonged parenteral nutrition
• Diuretic therapy (furosemide increases urinary calcium/phosphate losses)
• Chronic lung disease (on steroids)

Presentation:

• Often asymptomatic (detected on routine screening)
• Rib fractures (ventilated infants)
• Metaphyseal widening on routine chest radiographs

Management:

• Calcium: 120-140 mg/kg/day
• Phosphate: 60-90 mg/kg/day (critical)
• Vitamin D: 400-1000 IU/day
• Monitor: ALP (should not exceed 800-1000 IU/L), phosphate

Rickets in Adolescents ("Late-Onset Rickets")

Aetiology:

• Pubertal growth spurt increases calcium/phosphate demands
• Poor dietary intake (skipping meals, junk food, milk avoidance)
• Reduced outdoor activity (screen time)
• Cultural clothing (hijab)

Presentation:

• Diffuse bone pain ("growing pains" misdiagnosis)
• Genu valgum (knock knees) - typical of late-onset rickets (vs genu varum in toddlers)
• Delayed growth spurt

Management:

• High-dose vitamin D replacement (as per children)
• Ensure adequate calcium intake (critical during puberty)
• Address lifestyle factors (increase outdoor time, dietary counselling)

Pregnancy and Rickets/Osteomalacia

Maternal Vitamin D Deficiency:

• Consequences:
  • Neonatal hypocalcaemia (tetany, seizures in first 48 hours)
  • Neonatal rickets (craniotabes, delayed fontanelle)
  • Pre-eclampsia, gestational diabetes (vitamin D deficiency associations)
• Screening: Consider 25(OH)D screening in high-risk pregnancies (dark skin, minimal sun exposure, previous affected infant)

Management:

• Routine Supplementation: 400-600 IU/day for all pregnant women
• Treatment of Deficiency:
  • 1000-2000 IU/day (moderate deficiency)
  • 3000-4000 IU/day (severe deficiency) until repletion, then maintenance

Historical Complication - Pelvic Deformity:

• Women with severe childhood rickets develop contracted, deformed pelvis
• Obstructed Labour: Cephalopelvic disproportion → mandatory caesarean section
• Modern Rarity: Early childhood rickets treatment prevents this complication

---

10. Differential Diagnosis

Mimics of Rickets in Children

Hypophosphatasia:

• Pathology: Tissue-nonspecific alkaline phosphatase (TNSALP) deficiency (ALPL gene mutations)
• Key Discriminator: Low alkaline phosphatase (opposite of rickets)
• Other Features: Craniosynostosis, hypercalcaemia, elevated urinary phosphoethanolamine
• Radiological: Rickets-like changes but low ALP

Osteogenesis Imperfecta (OI):

• Pathology: Type I collagen defects
• Features: Multiple fractures, blue sclerae, dentinogenesis imperfecta, family history
• Biochemistry: Normal calcium, phosphate, ALP, vitamin D
• Radiological: Fractures (metaphyseal, diaphyseal), Wormian bones in skull, osteopenia

Non-Accidental Injury (NAI):

• Critical Differential: Fractures in rickets can be mistaken for abuse (and vice versa)
• Discriminators:
  • "Rickets: Metaphyseal cupping/fraying, elevated ALP, low vitamin D, consistent story"
  • "NAI: Metaphyseal corner fractures (classic), posterior rib fractures, inconsistent history, multiple fractures different ages, retinal haemorrhages"
• Action: If in doubt, full skeletal survey + biochemistry + safeguarding assessment

Blount's Disease (Tibia Vara):

• Pathology: Focal medial proximal tibial physis growth disturbance
• Features: Unilateral or asymmetrical bowing (rickets typically symmetrical)
• Biochemistry: Normal (not metabolic)
• Radiological: Beaking of medial metaphysis, fragmentation of medial epiphysis

Physiological Bowing:

• Normal: Mild genu varum in toddlers age 12-24 months (resolves spontaneously by age 3)
• Biochemistry: Normal
• Discriminator: Mild, symmetrical, no metaphyseal changes, normal growth

Mimics of Osteomalacia in Adults

Osteoporosis:

• Similarity: Low BMD, fractures
• Discriminators:
  • "Osteomalacia: Elevated ALP, low vitamin D, bone pain, myopathy, Looser's zones"
  • "Osteoporosis: Normal ALP, normal vitamin D, fractures often asymptomatic"
• Note: Conditions can coexist (osteomalacia causes secondary osteoporosis)

Paget's Disease of Bone:

• Similarity: Elevated ALP, bone pain, deformity
• Discriminators:
  • Paget's: Localised (monostotic/polyostotic), normal vitamin D, radiological features (cortical thickening, mixed lytic/sclerotic, "cotton wool" skull)
  • "Osteomalacia: Generalised, low vitamin D, Looser's zones"

Fibrous Dysplasia:

• Similarity: Bone pain, deformity, pathological fractures
• Discriminators: Localised monostotic/polyostotic lesions, "ground glass" radiological appearance, normal biochemistry (unless McCune-Albright syndrome)

Multiple Myeloma:

• Similarity: Bone pain, fractures, elevated ALP (sometimes)
• Discriminators: Anaemia, renal impairment, hypercalcaemia, lytic lesions on skeletal survey, monoclonal protein on SPEP/UPEP

---

11. Patient Education and Communication

Explaining Rickets to Parents

"What is Rickets?" "Rickets is a condition where your child's bones don't harden properly because they're not getting enough vitamin D. Think of bones like a brick wall. The bricks are calcium, but vitamin D is the cement that holds them together. Without enough vitamin D, the bones stay soft and bendy like rubber instead of hard like they should be."

"Why are my child's legs bowed?" "Because the bones are soft, they bend when your child stands and walks. It's like trying to build a tower with rubber instead of hard blocks - the weight makes them bend. The good news is that once we give vitamin D treatment and the bones harden, young children's bones often straighten out on their own as they grow. It's like magic - the body knows what shape the bones should be and fixes them naturally."

"How did this happen? Is it my fault?" "Rickets is very common and it's not anyone's fault. There are several reasons it happens:

• Not enough sunlight: Vitamin D comes from sunlight on the skin. If we live in a place with less sun, or if your child spends most time indoors, they can't make enough vitamin D.
• Dark skin: Children with darker skin need more sun exposure to make the same amount of vitamin D. This is why rickets is more common in children with darker skin living in countries like the UK.
• Diet: Breast milk is wonderful but doesn't have much vitamin D, which is why we recommend vitamin drops for breastfed babies.

What matters now is giving the treatment so the bones can heal."

"Will the treatment work?" "Yes, rickets treatment works excellently. We'll give high doses of vitamin D (drops or tablets), and we need to make sure your child gets enough calcium (usually from milk or supplements). Within a few weeks, you'll notice they're less irritable and the bone pain improves. The blood tests will get better in about 2-3 months. The bones will gradually harden over 6-12 months. For young children, the bowing often corrects itself. For older children, we sometimes need to help straighten the legs with surgery, but only after the bones are strong and healthy again."

"How long does treatment take?" "The initial high-dose treatment is usually 2-3 months. After that, your child will need a lower 'maintenance' dose every day to prevent rickets from coming back. This is usually just one drop or tablet per day - very simple. It's especially important if your child has dark skin or doesn't get much sun."

Explaining Osteomalacia to Adults

"What is Osteomalacia?" "Osteomalacia means 'soft bones'. It's the adult version of rickets. Your bones aren't hardening properly because you're deficient in vitamin D. This causes the bone pain you've been experiencing and explains why you've been feeling so weak."

"Why do I have this?" "Vitamin D deficiency is extremely common, especially in people who:

• Don't get much sunlight (housebound, office work, covering skin for cultural/religious reasons)
• Have darker skin (natural sun protection means you need more sun exposure than lighter-skinned people)
• Are older (skin becomes less efficient at making vitamin D)
• Have bowel problems that affect absorption

Your blood test showed very low vitamin D levels, which is why your bones haven't been hardening properly."

"What about the waddling walk?" "The waddling gait happens because vitamin D deficiency affects your muscles as well as your bones. Your hip and thigh muscles become weak, making it hard to walk normally. The good news is this improves quite quickly with vitamin D treatment - usually within a few weeks to months you'll notice your strength coming back."

"What is the treatment?" "We'll give you high-dose vitamin D tablets for 2-3 months to build your levels back up. After that, you'll take a lower maintenance dose every day to keep your levels healthy. We'll also make sure you're getting enough calcium (from diet or supplements). Within a few weeks, your bone pain should start improving. Your strength will gradually return over 2-3 months. We'll do blood tests to check everything is working."

"Will I need this forever?" "Most people need to stay on a maintenance dose of vitamin D long-term, especially if the reasons you became deficient (limited sun exposure, dark skin, etc.) haven't changed. The maintenance dose is low - usually just one tablet per day - and keeps you healthy. It's far easier than dealing with the pain and weakness of osteomalacia."

"Can I just get more sunlight instead of tablets?" "Sunlight is great for vitamin D, but it's often not enough on its own, especially in the UK. You'd need 15-30 minutes of midday sun on your face and arms several times per week, without sunscreen. For people with darker skin, you need even more. In winter, there's not enough UVB sunlight in the UK to make vitamin D (October to March). So a combination of safe sun exposure in summer and vitamin D tablets year-round is the best approach."

---

12. Evidence Base and Guidelines

Key Clinical Guidelines

1. Global Consensus Recommendations on Prevention and Management of Nutritional Rickets (2016)

   • Munns CF, Shaw N, Kiely M, et al.
   • J Clin Endocrinol Metab. 2016;101(2):394-415. doi:10.1210/jc.2015-2175
   • Summary: Authoritative global consensus providing evidence-based recommendations for prevention, diagnosis, and treatment of nutritional rickets. Recommends universal infant supplementation (400 IU/day), defines treatment protocols (high-dose loading followed by maintenance), and addresses high-risk populations. [1]

2. Diagnosis and Management of X-Linked Hypophosphataemia: A Practical Guide

   • Haffner D, Emma F, Eastwood DM, et al.
   • Nat Rev Nephrol. 2019;15(7):435-455. doi:10.1038/s41581-019-0152-5
   • Summary: Comprehensive practical guide for XLH diagnosis and management. Covers conventional therapy (phosphate/calcitriol) and emerging burosumab therapy. Emphasises multidisciplinary approach and long-term monitoring. [11]

3. Vitamin D Deficiency in Children and Its Management: Review of Current Knowledge and Recommendations

   • Misra M, Pacaud D, Petryk A, et al. (Drug and Therapeutics Committee, Lawson Wilkins Pediatric Endocrine Society)
   • Pediatrics. 2008;122(2):398-417. doi:10.1542/peds.2007-1894
   • Summary: Landmark review defining vitamin D deficiency, outlining screening and treatment strategies for children. Established treatment protocols widely adopted clinically. [2]

4. UK Department of Health: Vitamin D Supplementation Advice

   • Public Health England (2016)
   • Summary: Public health guidance recommending universal vitamin D supplementation for all infants 0-12 months (400 IU/day), high-risk groups, and consideration for all UK residents during winter months.

Landmark Studies and Evidence

Vitamin D Deficiency and Rickets Epidemiology:

5. Pettifor JM. "Nutritional rickets: deficiency of vitamin D, calcium, or both?"

   • Am J Clin Nutr. 2004;80(6 Suppl):1725S-1729S. doi:10.1093/ajcn/80.6.1725S
   • Key Finding: Established that rickets results from inadequate dietary calcium and/or vitamin D deficiency. Demonstrated geographic variation (calcipenic in Western nations vs calcium-deficient in some African/Asian regions). [3]

6. Thacher TD, Fischer PR, Tebben PJ, et al. "Increasing incidence of nutritional rickets: a population-based study in Olmsted County, Minnesota."

   • Mayo Clin Proc. 2013;88(2):176-183. doi:10.1016/j.mayocp.2012.10.018
   • Key Finding: Documented resurging rickets incidence in developed nations (USA), particularly in exclusively breastfed infants without supplementation and dark-skinned children. [14]

Pathophysiology and Vitamin D Metabolism:

7. Holick MF. "Vitamin D deficiency."
   • N Engl J Med. 2007;357(3):266-281. doi:10.1056/NEJMra070553
   • Key Finding: Comprehensive review of vitamin D synthesis, metabolism, and deficiency consequences. Established role of UVB exposure, age-related decline in synthesis, and role of melanin as natural sunblock. [17]

Burosumab - Revolutionary XLH Treatment:

8. Carpenter TO, Whyte MP, Imel EA, et al. "Burosumab Therapy in Children with X-Linked Hypophosphatemia."

   • N Engl J Med. 2018;378(21):1987-1998. doi:10.1056/NEJMoa1714641
   • Key Finding: Pivotal RCT demonstrating burosumab efficacy in children with XLH. Normalised serum phosphate in 94%, improved rickets severity scores, improved growth velocity, superior to conventional therapy. Led to FDA/EMA approval. [18]

9. Insogna KL, Briot K, Imel EA, et al. "A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis."

   • J Bone Miner Res. 2018;33(8):1383-1393. doi:10.1002/jbmr.3475
   • Key Finding: Demonstrated burosumab efficacy in adults with XLH - improved serum phosphate, reduced pain, improved physical function and quality of life. Established adult indication.

Tumour-Induced Osteomalacia:

10. Florenzano P, Gafni RI, Collins MT. "Tumor-induced osteomalacia."
    • Bone Rep. 2017;7:90-97. doi:10.1016/j.bonr.2017.09.002
    • Key Finding: Comprehensive review of TIO pathophysiology (FGF23-secreting mesenchymal tumours), diagnostic challenges (tumour localisation), and treatment (surgical resection curative; burosumab for unresectable cases). [6]

Clinical Features and Diagnosis:

11. Reginato AJ, Coquia JA. "Musculoskeletal manifestations of osteomalacia and rickets."
    • Best Pract Res Clin Rheumatol. 2003;17(6):1063-1080. doi:10.1016/j.berh.2003.09.004
    • Key Finding: Detailed characterisation of musculoskeletal features - Looser's zones as pathognomonic finding, proximal myopathy mechanism, distribution of pain and fractures. [10]

Vitamin D Deficiency in High-Risk Populations:

12. Clemens TL, Adams JS, Henderson SL, Holick MF. "Increased skin pigment reduces the capacity of skin to synthesise vitamin D3."
    • Lancet. 1982;1(8263):74-76. doi:10.1016/s0140-6736(82)90214-8
    • Key Finding: Demonstrated melanin reduces vitamin D synthesis efficiency by > 95% in dark-skinned individuals, explaining higher deficiency rates and rickets prevalence in darker-skinned populations at northern latitudes. [12]

Rickets vs Non-Accidental Injury:

13. Chapman T, Sugar N, Done S, et al. "Fractures in infants and toddlers with rickets."
    • Pediatr Radiol. 2010;40(7):1184-1189. doi:10.1007/s00247-009-1470-8
    • Key Finding: Characterised radiological features distinguishing rickets fractures from NAI. Emphasised importance of biochemical screening in all fracture cases and potential coexistence of rickets and abuse. [13]

Osteomalacia in Elderly:

14. Bhan A, Rao AD, Rao DS. "Osteomalacia as a result of vitamin D deficiency."
    • Endocrinol Metab Clin North Am. 2010;39(2):321-331. doi:10.1016/j.ecl.2010.02.001
    • Key Finding: Characterised osteomalacia in elderly populations - high prevalence in institutionalised patients, association with falls/fractures, often undiagnosed. Emphasised screening and prevention strategies. [15]

Post-Bariatric Surgery Bone Disease:

15. Stein EM, Carrelli A, Young P, et al. "Bariatric surgery results in cortical bone loss."
    • J Clin Endocrinol Metab. 2013;98(2):541-549. doi:10.1210/jc.2012-2394
    • Key Finding: Demonstrated high prevalence of vitamin D deficiency (50-70%) and secondary hyperparathyroidism post-bariatric surgery (malabsorption). Highlighted need for lifelong supplementation and monitoring. [16]

Rickets of Prematurity:

16. Backström MC, Kouri T, Kuusela AL, et al. "Bone isoenzyme of serum alkaline phosphatase and serum inorganic phosphate in metabolic bone disease of prematurity."
    • Acta Paediatr. 2000;89(7):867-873. doi:10.1080/080352500750043927
    • Key Finding: Established ALP > 800-1000 IU/L and low phosphate as markers of rickets in preterm infants. Defined phosphate supplementation as critical intervention.

FGF23 Biology:

17. Shimada T, Hasegawa H, Yamazaki Y, et al. "FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis."
    • J Bone Miner Res. 2004;19(3):429-435. doi:10.1359/JBMR.0301264
    • Key Finding: Elucidated FGF23 mechanism - renal phosphate wasting and suppression of 1α-hydroxylase. Explained pathophysiology of FGF23-mediated hypophosphataemic disorders (XLH, TIO).

Nephrocalcinosis in XLH:

18. Alon US, Levy-Olomucki R, Moore WV, et al. "Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets."
    • Clin J Am Soc Nephrol. 2008;3(3):658-664. doi:10.2215/CJN.04981107
    • Key Finding: Documented 25-70% nephrocalcinosis prevalence in conventionally-treated XLH patients. Highlighted long-term complications of phosphate/calcitriol therapy. [19]

Vitamin D and Muscle Function:

19. Ceglia L, Harris SS. "Vitamin D and its role in skeletal muscle."
    • Calcif Tissue Int. 2013;92(2):151-162. doi:10.1007/s00223-012-9645-y
    • Key Finding: Demonstrated vitamin D receptor expression in skeletal muscle and direct effects on muscle function (calcium flux, mitochondrial function). Explained myopathy mechanism in osteomalacia independent of bone disease. [9]

CKD-Mineral Bone Disorder:

20. Ketteler M, Block GA, Evenepoel P, et al. "Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update."
    • Kidney Int. 2017;92(1):26-36. doi:10.1016/j.kint.2017.04.006
    • Key Finding: Updated KDIGO guidelines for CKD-MBD management. Defined target ranges for calcium, phosphate, PTH by CKD stage. Recommended active vitamin D analogues (calcitriol, alfacalcidol) in CKD stages 3-5.

---

13. References

1. Munns CF, Shaw N, Kiely M, et al. Global Consensus Recommendations on Prevention and Management of Nutritional Rickets. J Clin Endocrinol Metab. 2016;101(2):394-415. doi:10.1210/jc.2015-2175

2. Misra M, Pacaud D, Petryk A, et al. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics. 2008;122(2):398-417. doi:10.1542/peds.2007-1894

3. Pettifor JM. Nutritional rickets: deficiency of vitamin D, calcium, or both? Am J Clin Nutr. 2004;80(6 Suppl):1725S-1729S. doi:10.1093/ajcn/80.6.1725S

4. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-281. doi:10.1056/NEJMra070553

5. Florenzano P, Hartley IR, Jimenez M, et al. Tumor-Induced Osteomalacia. Calcif Tissue Int. 2021;108(1):128-142. doi:10.1007/s00223-020-00691-6

6. Florenzano P, Gafni RI, Collins MT. Tumor-induced osteomalacia. Bone Rep. 2017;7:90-97. doi:10.1016/j.bonr.2017.09.002

7. Haffner D, Emma F, Eastwood DM, et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2019;15(7):435-455. doi:10.1038/s41581-019-0152-5

8. Carpenter TO, Whyte MP, Imel EA, et al. Burosumab Therapy in Children with X-Linked Hypophosphatemia. N Engl J Med. 2018;378(21):1987-1998. doi:10.1056/NEJMoa1714641

9. Ceglia L, Harris SS. Vitamin D and its role in skeletal muscle. Calcif Tissue Int. 2013;92(2):151-162. doi:10.1007/s00223-012-9645-y

10. Reginato AJ, Coquia JA. Musculoskeletal manifestations of osteomalacia and rickets. Best Pract Res Clin Rheumatol. 2003;17(6):1063-1080. doi:10.1016/j.berh.2003.09.004

11. Haffner D, Emma F, Eastwood DM, et al. Diagnosis and Management of X-Linked Hypophosphataemia: A Practical Guide. Nat Rev Nephrol. 2019;15(7):435-455. doi:10.1038/s41581-019-0152-5

12. Clemens TL, Adams JS, Henderson SL, Holick MF. Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. Lancet. 1982;1(8263):74-76. doi:10.1016/s0140-6736(82)90214-8

13. Chapman T, Sugar N, Done S, et al. Fractures in infants and toddlers with rickets. Pediatr Radiol. 2010;40(7):1184-1189. doi:10.1007/s00247-009-1470-8

14. Thacher TD, Fischer PR, Tebben PJ, et al. Increasing incidence of nutritional rickets: a population-based study in Olmsted County, Minnesota. Mayo Clin Proc. 2013;88(2):176-183. doi:10.1016/j.mayocp.2012.10.018

15. Bhan A, Rao AD, Rao DS. Osteomalacia as a result of vitamin D deficiency. Endocrinol Metab Clin North Am. 2010;39(2):321-331. doi:10.1016/j.ecl.2010.02.001

16. Stein EM, Carrelli A, Young P, et al. Bariatric surgery results in cortical bone loss. J Clin Endocrinol Metab. 2013;98(2):541-549. doi:10.1210/jc.2012-2394

17. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-281. doi:10.1056/NEJMra070553

18. Carpenter TO, Whyte MP, Imel EA, et al. Burosumab Therapy in Children with X-Linked Hypophosphatemia. N Engl J Med. 2018;378(21):1987-1998. doi:10.1056/NEJMoa1714641

19. Alon US, Levy-Olomucki R, Moore WV, et al. Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. Clin J Am Soc Nephrol. 2008;3(3):658-664. doi:10.2215/CJN.04981107

20. Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update. Kidney Int. 2017;92(1):26-36. doi:10.1016/j.kint.2017.04.006

---

(End of File)